24 Apr 2024 , 03:53 PM
Zydus Life shares experienced a decline on Wednesday, April 24, following the company's announcement regarding observations received from the USFDA for its injectable manufacturing site in Jarod, Gujarat.
The USFDA conducted an inspection of the facility from April 15 to April 23 and issued 10 observations. The company stated that it would collaborate closely with the USFDA to promptly address and respond to the observations.
Additionally, earlier in the week, Zydus Life launched Mirabegron Extended-Release tablets, 25 mg, for the treatment of overactive bladder in the US market.
Mirabegron is prescribed for overactive bladder symptoms such as urge urinary incontinence, urgency, and urinary frequency. The tablet will be manufactured at the company's formulation manufacturing facility in Ahmedabad SEZ, India.
At the time of writing on April 24, the stock was down by 2.76% at ₹933 apiece.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.